• Approximately 70% of adult patients treated with CRENESSITY achieved and sustained physiologic‑range glucocorticoid dosing at two years
  • 75% of patients originally taking dexamethasone transitioned off this treatment, enabling a more physiologic glucocorticoid regimen without compromising androgen control
  • Findings reinforce durable efficacy and a favorable long‑term safety profile in largest interventional trial to date conducted in classic congenital adrenal hyperplasia

SAN DIEGO, April 22, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study demonstrating sustained, substantial reductions in glucocorticoid (GC) doses in adults with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont), with approximately 70% of patients achieving GC doses within the physiologic range. These data build upon previously reported one-year results and were presented at the American Association of Clinical Endocrinology 2026 Annual Meeting in Las Vegas.